Genmab — Maj 2016
-
-
Daratumumab is basically being combined with just about anything that you can think of in the context of phase III studies http://global.onclive.com/insights/Immunotherapy-in-multiple-myeloma/antibodies-in-combination-therapy-for-myeloma
-

-
Vitae har med en markedsværdi på 200 millioner dollar et stykke vej til Anacors, men har med deres RORgt inhibitor sigte mod psoriasis og med LXR mod AD. Begge stoffer har chance for at blive first in class, så det siger lidt om mulighederne hvis de skulle gå hen og få succes. Lang vej endnu men alligevel.........
-
Anonyme burde læse denne her: http://www.daytrader.dk/kobssignal-genmab-brudt-1000/?utm_source=e-mail&utm_medium=e-mail&utm_campaign=e-mail
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind